Directorate Change

Oxford, UK - 11 March 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that CDMO expert, Peter Soelkner, will join the Board as a Non-Executive Director, effective from 15 March 2024. Concurrently, as part of Oxford Biomedica's transformation into a pure-play CDMO, the Company announces that Catherine Moukheibir and Dr. Michael Hayden have informed the Board that they do not intend to stand for re-election at the upcoming Annual General Meeting in June 2024. Dr. Michael Hayden will continue to be an adviser to the Science and Technology Advisory Committee.

Peter Soelkner has more than 30 years' experience in the global pharmaceutical services industry with significant CDMO expertise. He is currently Managing Director of Vetter Pharma, a global Aseptic Filling and Packaging CDMO, where over the past 15 years he has helped grow revenues from $200 million to more than $1 billion. Prior to Vetter, Mr. Soelkner held various senior positions at Sartorius including Vice President of the Americas region where he expanded the global footprint of the business across the US and multiple sectors. He has an MBA from Columbia Business School, New York and Masters in Chemical Engineering from TU Dortmund University, Germany.

Dr. Roch Doliveux, Non-Executive Chairman of Oxford Biomedica, commented: "Alongside OXB's transformation to become a pure-play viral vector CDMO, the Board of Directors has reviewed its breadth of skills and taken the decision to streamline the Board whilst bolstering its CDMO expertise. In light of this, we are delighted to welcome Peter Soelkner given his impressive track record in significantly growing Vetter, a leading global CDMO from $200m to more than $1bn in revenues. In parallel, Catherine Moukheibir and Dr. Michael Hayden, who have played a defining role in shaping OXB's new strategy, both volunteered not to stand for re-election at the next AGM given that their strengths lie more in therapeutics rather than CDMO. I would like to personally thank Catherine and Michael for their impeccable service, loyalty and valuable insights."

Peter Soelkner commented: "I am pleased to be joining this innovative, client-centric, global business at such an exciting juncture in the Company's journey. In my view Oxford Biomedica is extremely well-positioned as a pure-play CDMO and I am excited to apply my skillset and experience to help deliver the strategy to clients, enabling them to deliver life-changing therapies to patients."

Relevant disclosures

There are no disclosures required to be made in accordance with LR 9.6.13R.